Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Clinical Trials for Bio-Thera Solutions
Explore 16 clinical trials worldwide
Search
Showing 1-16 of 16 trials
Active filters:
Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruiting
Sponsor: Bio-Thera Solutions
Clinical Trials (16)
NCT07180862
A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants
PHASE1
Not yet recruiting
140 participants
Started: Sep 30, 2025 · Completed: Nov 30, 2027
1 condition
1 sponsor
1 location
NCT06545617
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
PHASE1/PHASE2
Not yet recruiting
170 participants
Started: Jan 31, 2025 · Completed: Jan 31, 2028
3 conditions
1 sponsor
0 locations
NCT06376136
A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors
PHASE1/PHASE2
Recruiting
216 participants
Started: May 8, 2024 · Completed: Dec 9, 2026
1 condition
1 sponsor
1 location
NCT06341114
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors
PHASE1/PHASE2
Active, not recruiting
112 participants
Started: Apr 12, 2024 · Completed: Jul 28, 2026
1 condition
1 sponsor
1 location
NCT06139536
Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
PHASE1
Recruiting
210 participants
Started: Mar 6, 2024 · Completed: Feb 28, 2026
1 condition
1 sponsor
3 locations
NCT06123884
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
PHASE2/PHASE3
Recruiting
526 participants
Started: Dec 13, 2023 · Completed: Jan 31, 2027
1 condition
1 sponsor
1 location
NCT06094179
Evaluate the Safety, Tolerability of BAT6026
PHASE1/PHASE2
Recruiting
33 participants
Started: Nov 9, 2023 · Completed: Oct 15, 2025
1 condition
1 sponsor
1 location
NCT06044350
A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders
PHASE2
Recruiting
162 participants
Started: Aug 1, 2023 · Completed: May 31, 2026
1 condition
1 sponsor
45 locations
NCT05879627
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
PHASE1
Active, not recruiting
250 participants
Started: Jan 17, 2023 · Completed: Jul 1, 2026
1 condition
2 sponsors
1 location
NCT05620017
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
PHASE1
Not yet recruiting
182 participants
Started: Nov 30, 2022 · Completed: Dec 31, 2025
1 condition
1 sponsor
0 locations
NCT05439629
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
PHASE3
Active, not recruiting
488 participants
Started: Jul 28, 2022 · Completed: Jun 30, 2025
1 condition
1 sponsor
48 locations
NCT05378737
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection
PHASE1
Recruiting
216 participants
Started: Jul 6, 2022 · Completed: Dec 31, 2025
1 condition
1 sponsor
17 locations
NCT05767060
BAT7104 Injection in Patients with Advanced Malignant Tumors.
PHASE1
Recruiting
42 participants
Started: Jan 20, 2022 · Completed: Dec 20, 2024
1 condition
2 sponsors
1 location
NCT05180526
Assessment of Safety , Clinical Efficacy with QLETLI in Non-infectious Uveitis (UV)
PHASE4
Active, not recruiting
60 participants
Started: Dec 27, 2021 · Completed: Dec 30, 2024
1 condition
1 sponsor
7 locations
NCT05105971
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
PHASE1
Active, not recruiting
30 participants
Started: Dec 23, 2021 · Completed: Nov 14, 2024
1 condition
1 sponsor
1 location
NCT05155722
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy with BAT1308 in Advanced Solid Tumors
PHASE1
Active, not recruiting
148 participants
Started: Sep 17, 2020 · Completed: Dec 31, 2025
1 condition
1 sponsor
1 location